A heavyweight domestic GLP-1 weight loss drug has arrived! The National Medical Products Administration has approved the listing of Marbidexide injection.

Recently, the National Medical Products Administration approved the marketing of the class 1 innovative drug Mazdutide Injection (trade name: Xinermei) submitted by INNOVENT BIO Pharmaceutical (Suzhou) Co., Ltd. This drug is used for long-term weight control in adult patients on the basis of controlling diet and increasing physical activity, with an initial body mass index (BMI) of BMI 28 kg/m2 (obesity); or BMI 24 kg/m2 (overweight), and with at least one weight-related comorbidity (such as hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, etc.). The marketing of this drug provides patients with a new treatment option. This article was selected from the "National Medical Products Administration", edited by GMTEight: Xu Wenqiang.